Login to Your Account



BMS Hopes for Further Buyout Discussions with ImClone

By Catherine Hollingsworth


Friday, September 12, 2008
Bristol-Myers Squibb Co., in a letter to partner ImClone Systems Inc., showed no sign of backing down from its offer to buy ImClone for $60 per share, a bid that was rejected this week by a special committee of ImClone's board. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription